Ida Marie Lind Rasmussen

Ida Marie Lind Rasmussen

Auto-generated profile, based on publicly available information

Ida Marie Lind Rasmussen

Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Acta Oncologica
Verified
Journal Article
Closed access
IRIda Marie Lind Rasmussen
Ida Marie Lind Rasmussen
AMAnne Kirstine Hundahl Moeller
Anne Kirstine Hundahl Moeller
ASAnne Vest Sørensen
Anne Vest Sørensen
GPGitte F. Persson
Gitte F. Persson
GTGry Assam Taarnhøj
Gry Assam Taarnhøj
HPHelle Pappot
Helle Pappot

15 September 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
IRIda Marie Lind Rasmussen
Ida Marie Lind Rasmussen
ASAnne Vest Sørensen
Anne Vest Sørensen
AMAnne Kirstine Møller
Anne Kirstine Møller
GPGitte F. Persson
Gitte F. Persson
JPJesper Andreas Palshof
Jesper Andreas Palshof
HPHelle Pappot
Helle Pappot
Background: No phase 3 studies have yet been conducted for patients with non–clear cell (CC) renal cell carcinoma (RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumor morphology. Consequently, there is no evidence of the optimal treatment, and new approaches are needed. One approach is individualizing treatment based on the gene sequencing of tumor tissue. Additionally, recent studies involving the patient-reported outcomes (PROs) of patients treated for metastatic cancer have shown significant benefits for quality of life, median overall survival, and overall survival. The use of gene sequencing and PROs can be of great importance to patients with rare cancer types, including patients with non-CC RCC, and should be investigated in clinical trials, especially for cases where evidence based on phase 3 studies is difficult to obtain. Objective: We describe the INDIGO study, in which patients, based on gene analyses, will be allocated into 4 treatment arms containing 14 treatments and use electronic PROs. We aim to improve the treatment of patients with non-CC RCC. The end points in the study will be the overall response rate (complete and partial) in the total patient population, which will be based on the RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1 criteria, and the time to treatment failure. Methods: INDIGO is a prospective phase 2 trial, and 30 patients will be enrolled. The patients will receive systemic treatment based on genetic analyses of their tumor tissue. All patients will receive electronic questionnaires in a dedicated app—a questionnaire regarding symptoms and side effects and another regarding health-related quality of life. Depending on the treatment regimen, the patients will be seen by a medical doctor every third, fourth, or sixth week, and the effect of the systemic treatment will be evaluated every 6 weeks via a computed tomography scan. The study has been approved by the Danish Medicines Agency and the National Committee on Health Research Ethics (approval number: H-19041833), complies with good clinical practice guidelines, follows the General Data Protection Regulation, and is registered at the Capital Region of Denmark. Results: Recruitment started in March 2020, and at the time of submitting this paper (June 2022), a total of 9 patients have been enrolled. Conclusions: We aim to explore methods for improving the treatment outcomes of patients with non-CC RCC, and the INDIGO study will contribute further data on personalized medicine for rare types of RCC and provide new knowledge on the active use of electronic PROs. Trial Registration: ClinicalTrials.gov NCT04644432, https://clinicaltrials.gov/ct2/show/NCT04644432 ; European Union Drug Regulating Authorities Clinical Trials Database 2019-001316-38, https://tinyurl.com/2p8mb4aw International Registered Report Identifier (IRRID): DERR1-10.2196/36632

19 January 2022 in JMIR Preprints
Verified
Preprint
Open access
IRIda Marie Rasmussen
Ida Marie Rasmussen
ASAnne Vest Sørensen
Anne Vest Sørensen
AMAnne Kirstine Hundahl Moeller
Anne Kirstine Hundahl Moeller
GPGitte Persson
Gitte Persson
JPJesper Andreas Palshof
Jesper Andreas Palshof
HPHelle Pappot
Helle Pappot
BACKGROUND No phase III studies have yet been conducted for patients with non-clear cell renal cell carcinoma (non-cc RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumour morphology. Consequently, there is no evidence of the optimal treatment and new approaches are needed. An active, real-time use of patient-reported outcomes (PRO) is gaining ground in oncology and allows for individualization of care for the patients, which also is warranted in the present population. Recent studies with PRO in patients treated for metastatic cancer have shown a significant benefit in quality of life, median- and overall survival. The use of PRO as endpoint in clinical studies can be of great importance to patients with rare cancer types including patients with non-cc RCC, for whom treatment is highly individualised, and evidence based on phase III studies is difficult to achieve. OBJECTIVE We describe the INDIGO study with focus on active and passive use of electronic patient-reported outcomes (ePRO) in a complex study setting with four different treatment arms containing fourteen treatment options for patients with non-cc RCC. By using new treatments and adding ePRO to the treatment trajectory we aim to improve treatment of the rare subtypes of RCC. METHODS INDIGO is a prospective phase II trial and 30 patients will be enrolled. The patients receive systemic treatment based on genetic analyses of their tumour tissue. All patients will receive two electronic questionnaires: one questionnaire regarding symptoms and side effects is sent weekly and one regarding health-related quality of life is sent every four weeks. The questionnaires are completed in a dedicated electronic app with an interface developed specifically for the INDIGO study. Healthcare professionals daily assess the incoming responses from the patients and can contact the patient to initiate or improve supportive care. In relation to PRO, the study has the following endpoints: Use of PRO tools during treatment both in terms of completion of weekly questionnaires, in terms of possible patterns in the completion in different subgroups of the patients and in terms of following the instructions regarding contact to the hospital. RESULTS The INDIGO study is approved by the Danish Medicines Agency, the National Committee on Health Research Ethics and complies with Good Clinical Practice guidelines, follow General Data Protection Regulation and is registered at the Capital Region of Denmark. Recruitment of patients started in March 2020. CONCLUSIONS We aim to explore methods to improve treatment outcome for patients with non-cc RCC and this feasibility study will demonstrate how ePRO can be implemented in a basket trial by applying active and passive PRO to a phase II treatment study. CLINICALTRIAL ClinicalTrials.gov Identifier: NCT04644432 EudraCT: 2019-001316-38 Danish National Committee on health research ethics: H-19041833